205 related articles for article (PubMed ID: 21647676)
1. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Gallicchio L; Macdonald R; Wood B; Rushovich E; Helzlsouer KJ
Breast Cancer Res Treat; 2011 Nov; 130(2):569-77. PubMed ID: 21647676
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
3. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer.
Gallicchio L; MacDonald R; Helzlsouer KJ
J Cancer Res Clin Oncol; 2013 May; 139(5):837-43. PubMed ID: 23408333
[TBL] [Abstract][Full Text] [Related]
5. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
6. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Stearns V; Chapman JA; Ma CX; Ellis MJ; Ingle JN; Pritchard KI; Budd GT; Rabaglio M; Sledge GW; Le Maitre A; Kundapur J; Liedke PE; Shepherd LE; Goss PE
J Clin Oncol; 2015 Jan; 33(3):265-71. PubMed ID: 25512454
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
Kidwell KM; Harte SE; Hayes DF; Storniolo AM; Carpenter J; Flockhart DA; Stearns V; Clauw DJ; Williams DA; Henry NL
Cancer; 2014 Aug; 120(16):2403-11. PubMed ID: 24802413
[TBL] [Abstract][Full Text] [Related]
8. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
9. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
Kadakia KC; Kidwell KM; Seewald NJ; Snyder CF; Storniolo AM; Otte JL; Flockhart DA; Hayes DF; Stearns V; Henry NL
Breast Cancer Res Treat; 2017 Jul; 164(2):411-419. PubMed ID: 28451964
[TBL] [Abstract][Full Text] [Related]
10. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
Baumgart J; Nilsson K; Stavreus Evers A; Kunovac Kallak T; Kushnir MM; Bergquist J; Sundström Poromaa I
Climacteric; 2014 Feb; 17(1):48-54. PubMed ID: 23647561
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms.
Helzlsouer KJ; Gallicchio L; MacDonald R; Wood B; Rushovich E
Breast Cancer Res Treat; 2012 Jan; 131(1):277-85. PubMed ID: 21904883
[TBL] [Abstract][Full Text] [Related]
12. Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Menas P; Merkel D; Hui W; Lawton J; Harper A; Carro G
J Oncol Pharm Pract; 2012 Dec; 18(4):387-93. PubMed ID: 22277833
[TBL] [Abstract][Full Text] [Related]
13. Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Gibson K; O'Bryant CL
J Oncol Pharm Pract; 2008 Sep; 14(3):139-45. PubMed ID: 18719068
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Winters L; Habin K; Gallagher J
Clin J Oncol Nurs; 2007 Jun; 11(3):433-9. PubMed ID: 17623627
[TBL] [Abstract][Full Text] [Related]
15. Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer.
Kyvernitakis I; Albert US; Kalder M; Winarno AS; Hars O; Hadji P
Climacteric; 2015 Feb; 18(1):63-8. PubMed ID: 24884402
[TBL] [Abstract][Full Text] [Related]
16. Appraising adjuvant aromatase inhibitor therapy.
Perez EA
Oncologist; 2006; 11(10):1058-69. PubMed ID: 17110624
[TBL] [Abstract][Full Text] [Related]
17. Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy.
Hadji P; Kauka A; Bauer T; Tams J; Hasenburg A; Kieback DG
Climacteric; 2012 Oct; 15(5):460-6. PubMed ID: 22321061
[TBL] [Abstract][Full Text] [Related]
18. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
19. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
[TBL] [Abstract][Full Text] [Related]
20. [Aromatase inhibitors in adjuvant setting in breast cancer].
Spano JP; Khayat D; Delozier T
Bull Cancer; 2004 Dec; 91 Suppl 4():S239-43. PubMed ID: 15899615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
